Belzutifan for patients with von Hippel-Lindau disease-associated CNS haemangioblastomas (LITESPARK-004): a multicentre, single-arm, phase 2 study
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Belzutifan for Renal Cell Carcinoma in von Hippel–Lindau Disease
Jonasch, E., Donskov, F., Iliopoulos, O., Rathmell, W. K., Narayan, V. K., Maughan, B. L., Oudard, S., Else, T., Maranchie, J. K., Welsh, S. J., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2103425 · Cited by 714
Self-citation
Research works printed but not linked: 29
- Varshney, 2017, A review of Von Hippel-Lindau syndrome, J Kidney Cancer VHL, 4, 20, 10.15586/jkcvhl.2017.88 · DOI · Paper page
- Ganeshan, 2018, Tumors in von Hippel-Lindau syndrome: from head to toe-comprehensive state-of-the-art review, Radiographics, 38, 849, 10.1148/rg.2018170156 · DOI
- Kanno, 2014, Pathological and clinical features and management of central nervous system hemangioblastomas in von Hippel-Lindau disease, J Kidney Cancer VHL, 1, 46, 10.15586/jkcvhl.2014.12 · DOI
- Klingler, 2020, Hemangioblastoma and von Hippel-Lindau disease: genetic background, spectrum of disease, and neurosurgical treatment, Childs Nerv Syst, 36, 2537, 10.1007/s00381-020-04712-5 · doi:10.1007/s00381-020-04712-5
- Chittiboina, 2015, Von Hippel-Lindau disease, Handb Clin Neurol, 132, 139, 10.1016/B978-0-444-62702-5.00010-X · DOI · Paper page
- Ordookhanian, 2017, Management strategies and outcomes for VHL-related craniospinal hemangioblastomas, J Kidney Cancer VHL, 4, 37, 10.15586/jkcvhl.2017.90 · DOI
- Wind, 2011, Management of von Hippel-Lindau disease-associated CNS lesions, Expert Rev Neurother, 11, 1433, 10.1586/ern.11.124 · doi:10.1586/ern.11.124
- Lonser, 2014, Prospective natural history study of central nervous system hemangioblastomas in von Hippel-Lindau disease, J Neurosurg, 120, 1055, 10.3171/2014.1.JNS131431 · DOI · Paper page
- Binderup, 2017, Survival and causes of death in patients with von Hippel-Lindau disease, J Med Genet, 54, 11, 10.1136/jmedgenet-2016-104058 · DOI · Paper page
- Krüger, 2014, Current diagnostic and therapeutic strategies in treatment of CNS hemangioblastomas in patients with VHL, J Transl Med Epidemiol, 2
- Simone, 2011, Infratentorial craniospinal irradiation for von Hippel-Lindau: a retrospective study supporting a new treatment for patients with CNS hemangioblastomas, Neuro-oncol, 13, 1030, 10.1093/neuonc/nor085 · doi:10.1093/neuonc/nor085
- Goyal, 2016, Stereotactic radiosurgery in hemangioblastoma: Experience over 14 years, J Neurosci Rural Pract, 7, 23, 10.4103/0976-3147.172165 · doi:10.4103/0976-3147.172165
- Yin, 2020, Incidence, prognostic factors and survival for hemangioblastoma of the central nervous system: analysis based on the surveillance, epidemiology, and end results database, Front Oncol, 10, 10.3389/fonc.2020.570103 · doi:10.3389/fonc.2020.570103
- Omar, 2012, Bevacizumab for the treatment of surgically unresectable cervical cord hemangioblastoma: a case report, J Med Case Rep, 6, 238, 10.1186/1752-1947-6-238 · doi:10.1186/1752-1947-6-238
- Nguyen, 2018, Von Hippel-Lindau with early onset of hemangioblastoma and multiple drop-metastases like spinal lesions: a case report, Medicine (Baltimore), 97, 10.1097/MD.0000000000012477 · doi:10.1097/md.0000000000012477
- Capitanio, 2013, Mechanisms, indications and results of salvage systemic therapy for sporadic and von Hippel-Lindau related hemangioblastomas of the central nervous system, Crit Rev Oncol Hematol, 86, 69, 10.1016/j.critrevonc.2012.10.001 · DOI
- Zamarud, 2023, The outcome of central nervous system hemangioblastomas in Von Hippel-Lindau (VHL) disease treated with belzutifan: a single-institution retrospective experience, J Neurooncol, 165, 373, 10.1007/s11060-023-04496-z · DOI
- Neth, 2023, Belzutifan in adults with VHL-associated central nervous system hemangioblastoma: a single-center experience, J Neurooncol, 164, 239, 10.1007/s11060-023-04395-3 · DOI
- Dhawan, 2022, First clinical experience with belzutifan in von Hippel-Lindau disease associated CNS hemangioblastoma, CNS Oncol, 11, 10.2217/cns-2022-0008 · DOI
- Lonser, 2005, Edema is a precursor to central nervous system peritumoral cyst formation, Ann Neurol, 58, 392, 10.1002/ana.20584 · DOI
- Padhi, 2011, A 10-year retrospective study of hemangioblastomas of the central nervous system with reference to von Hippel-Lindau (VHL) disease, J Clin Neurosci, 18, 939, 10.1016/j.jocn.2010.12.050 · doi:10.1016/j.jocn.2010.12.050
- Wanebo, 2003, The natural history of hemangioblastomas of the central nervous system in patients with von Hippel-Lindau disease, J Neurosurg, 98, 82, 10.3171/jns.2003.98.1.0082 · DOI · Paper page
- Butman, 2008, Neurologic manifestations of von Hippel-Lindau disease, JAMA, 300, 1334, 10.1001/jama.300.11.1334 · DOI
- Ivanov, 2001, Expression of hypoxia-inducible cell-surface transmembrane carbonic anhydrases in human cancer, Am J Pathol, 158, 905, 10.1016/S0002-9440(10)64038-2 · DOI · Paper page
- Kciuk, 2022, Targeting carbonic anhydrase IX and XII isoforms with small molecule inhibitors and monoclonal antibodies, J Enzyme Inhib Med Chem, 37, 1278, 10.1080/14756366.2022.2052868 · DOI
- Skuli, 2012, Endothelial HIF-2α regulates murine pathological angiogenesis and revascularization processes, J Clin Invest, 122, 1427, 10.1172/JCI57322 · DOI · Paper page
- Srinivasan, 2022, LBA69 Belzutifan, a HIF-2α inhibitor, for von Hippel-Lindau (VHL) disease-associated neoplasms: 36 months of follow-up of the phase II LITESPARK-004 study, Ann Oncol, 33, S1433, 10.1016/j.annonc.2022.08.074 · DOI
- Saeed, 2023, Fatal intracranial hemorrhage with belzutifan in von Hippel-Lindau disease-associated hemangioblastoma: a case report, JCO Precis Oncol, 7
- Trinh, 2023, FDA approval summary: belzutifan for VHL disease tumors—letter, Clin Cancer Res, 29, 684, 10.1158/1078-0432.CCR-22-2968 · DOI
Cited by
Srinivasan, R., Iliopoulos, O., Beckermann, K. E., Narayan, V., Maughan, B. L., Oudard, S., Else, T., Maranchie, J. K., Iversen, A. B., Cornell, J., et al. (2025) · The Lancet Oncology · doi:10.1016/s1470-2045(25)00099-3 · Cited by 50
Self-citation
Metadata
- Authors
- Iliopoulos, O., Iversen, A. B., Narayan, V., Maughan, B. L., Beckermann, K. E., Oudard, S., Else, T., Maranchie, J. K., Goldberg, C. M., Fu, W., Perini, R. F., Liu, Y., Linehan, W. M., Srinivasan, R., & Jonasch, E.
- Venue
- The Lancet Oncology
- Publisher
- Elsevier BV
- Published
- 2024-10
- Volume
- 25
- Issue
- 10
- Pages
- 1325-1336
- ISSN
- 1470-2045
- Cited by
- 46
- References
- 1
- Language
- en
- Update notices
- erratum (2024-11-01)
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- doi.org/10.15223/policy-017 (stm-asf)
- doi.org/10.15223/policy-037 (stm-asf)
- doi.org/10.15223/policy-012 (stm-asf)
- doi.org/10.15223/policy-029 (stm-asf)
- doi.org/10.15223/policy-004 (stm-asf)
- Funders
- Center for Cancer Research (UO1 CA236489)
- National Institutes of Health
- Merck Sharp and Dohme United Kingdom
- National Cancer Institute
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Belzutifan for patients with von Hippel-Lindau disease-associated CNS haemangioblastomas (LITESPARK-004): a multicentre, single-arm, phase 2 study. https://app.cochat.ai/papers/10.1016/s1470-2045(24)00389-9
- The paper
- Iliopoulos, O., Iversen, A. B., Narayan, V., Maughan, B. L., Beckermann, K. E., Oudard, S., Else, T., Maranchie, J. K., Goldberg, C. M., Fu, W., Perini, R. F., Liu, Y., Linehan, W. M., Srinivasan, R., & Jonasch, E. (2024). Belzutifan for patients with von Hippel-Lindau disease-associated CNS haemangioblastomas (LITESPARK-004): a multicentre, single-arm, phase 2 study. The Lancet Oncology. https://doi.org/10.1016/s1470-2045(24)00389-9
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.